Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 606802, 12 pages
http://dx.doi.org/10.4061/2010/606802
Review Article

CSF Biomarkers for Alzheimer's Disease Diagnosis

Department of Biosciences and Bioengineering, IIT Bombay, Powai, Mumbai 400076, India

Received 15 March 2010; Accepted 27 April 2010

Academic Editor: Lucilla Parnetti

Copyright © 2010 A. Anoop et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. E. Hebert, P. A. Scherr, J. L. Bienias, D. A. Bennett, and D. A. Evans, “Alzheimer disease in the US population: prevalence estimates using the 2000 census,” Archives of Neurology, vol. 60, no. 8, pp. 1119–1122, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H. M. Arrighi, “Forecasting the global burden of Alzheimer's disease,” Alzheimer's and Dementia, vol. 3, no. 3, pp. 186–191, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Selkoe, “Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases,” Nature Cell Biology, vol. 6, no. 11, pp. 1054–1061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. N.D. Lazo, S. K. Maji, E. A. Fradinger et al., “The amyloid beta protein,” in Amyloid Protein-The Beta Sheet Conformation and Disease, J. D. Sipe, Ed., pp. 385–491, Wiley-VCH Publishers, Weinheim, Germany, 2005. View at Google Scholar
  5. I. Grundke-Iqbal, K. Iqbal, and Y.-C. Tung, “Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 13, pp. 44913–4917, 1986. View at Google Scholar · View at Scopus
  6. I. Grundke-Iqbal, K. Iqbal, and M. Quinlan, “Microtubule-associated protein tau. A component of Alzheimer paired helical filaments,” The Journal of Biological Chemistry, vol. 261, no. 13, pp. 6084–6089, 1986. View at Google Scholar · View at Scopus
  7. J. C. Morris, “The challenge of characterizing normal brain aging in relation to Alzheimer's disease,” Neurobiology of Aging, vol. 18, no. 4, pp. 388–389, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. J. C. Morris and J. L. Price, “Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease,” Journal of Molecular Neuroscience, vol. 17, no. 2, pp. 101–118, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. J. Perrin, A. M. Fagan, and D. M. Holtzman, “Multimodal techniques for diagnosis and prognosis of Alzheimer's disease,” Nature, vol. 461, no. 7266, pp. 916–922, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg, “Cerebrospinal fluid and plasma biomarkers in Alzheimer disease,” Nature Reviews Neurology, vol. 6, no. 3, pp. 131–144, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. C. M. Clark, C. Davatzikos, A. Borthakur et al., “Biomarkers for early detection of Alzheimer pathology,” NeuroSignals, vol. 16, no. 1, pp. 11–18, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. R. J. Killiany, T. Gomez-Isla, M. Moss et al., “Use of structural magnetic resonance imaging to predict who will get Alzheimers disease,” Annals of Neurology, vol. 47, no. 4, pp. 430–439, 2000. View at Google Scholar · View at Scopus
  13. C. J. A. Moulin, M. Laine, J. O. Rinne et al., “Brain function during multi-trial learning in mild cognitive impairment: a PET activation study,” Brain Research, vol. 1136, no. 1, pp. 132–141, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. C. A. Mathis, Y. Wang, D. P. Holt, G.-F. Huang, M. L. Debnath, and W. E. Klunk, “Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents,” Journal of Medicinal Chemistry, vol. 46, no. 13, pp. 2740–2754, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Hye, S. Lynham, M. Thambisetty et al., “Proteome-based plasma biomarkers for Alzheimer's disease,” Brain, vol. 129, no. 11, pp. 3042–3050, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. Y.-M. Kuo, T. A. Kokjohn, W. Kalback et al., “Amyloid-β peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma,” Biochemical and Biophysical Research Communications, vol. 268, no. 3, pp. 750–756, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Fukumoto, M. Tennis, J. J. Locascio, B. T. Hyman, J. H. Growdon, and M. C. Irizarry, “Age but not diagnosis is the main predictor of plasma amyloid β-protein levels,” Archives of Neurology, vol. 60, no. 7, pp. 958–964, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Maddalena, A. Papassotiropoulos, B. Müller-Tillmanns et al., “Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to β-amyloid peptide42,” Archives of Neurology, vol. 60, no. 9, pp. 1202–1206, 2003. View at Publisher · View at Google Scholar · View at Scopus
  19. C. D. Aluise, R. A. Sowell, and D. A. Butterfield, “Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1782, no. 10, pp. 549–558, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Kantarci and C. R. Jack Jr., “Neuroimaging in Alzheimer disease: an evidence-based review,” Neuroimaging Clinics of North America, vol. 13, no. 2, pp. 197–209, 2003. View at Google Scholar · View at Scopus
  21. L. J. Thal, K. Kantarci, E. M. Reiman et al., “The role of biomarkers in clinical trials for Alzheimer disease,” Alzheimer Disease and Associated Disorders, vol. 20, no. 1, pp. 6–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. M. E. Raichle and M. A. Mintun, “Brain work and brain imaging,” Annual Review of Neuroscience, vol. 29, pp. 449–476, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. G. B. Frisoni, “Structural imaging in the clinical diagnosis of Alzheimer's disease: problems and tools,” Journal of Neurology Neurosurgery and Psychiatry, vol. 70, no. 6, pp. 711–718, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Scheltens, N. Fox, F. Barkhof, and C. De Carli, “Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion,” Lancet Neurology, vol. 1, no. 1, pp. 13–21, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Barnes, J. L. Whitwell, C. Frost, K. A. Josephs, M. Rossor, and N. C. Fox, “Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration,” Archives of Neurology, vol. 63, no. 10, pp. 1434–1439, 2006. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Barnes, A. K. Godbolt, C. Frost et al., “Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD,” Neurobiology of Aging, vol. 28, no. 1, pp. 20–28, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Whitwell and C. R. Jack Jr., “Comparisons between Alzheimer disease, frontotemporal lobar degeneration, and normal aging with brain mapping,” Topics in Magnetic Resonance Imaging, vol. 16, no. 6, pp. 409–425, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. J. T. Becker, M. A. Mintun, K. Aleva, M. B. Wiseman, T. Nichols, and S. T. DeKosky, “Compensatory reallocation of brain resources supporting verbal episodic memory in Alzheimer's disease,” Neurology, vol. 46, no. 3, pp. 692–700, 1996. View at Google Scholar · View at Scopus
  29. C. L. Grady, M. L. Furey, P. Pietrini, B. Horwitz, and S. I. Rapoport, “Altered brain functional connectivity and impaired short-term memory in Alzheimer's disease,” Brain, vol. 124, no. 4, pp. 739–756, 2001. View at Google Scholar · View at Scopus
  30. J. L. Woodard, S. T. Grafton, J. R. Votaw, R. C. Green, M. E. Dobraski, and J. M. Hoffman, “Compensatory recruitment of neural resources during overt rehearsal of word lists in Alzheimer's disease,” Neuropsychology, vol. 12, no. 4, pp. 491–504, 1998. View at Publisher · View at Google Scholar · View at Scopus
  31. M. A. Mintun, G. N. Larossa, Y. I. Sheline et al., “[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease,” Neurology, vol. 67, no. 3, pp. 446–452, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. W. E. Klunk, H. Engler, A. Nordberg et al., “Imaging brain amyloid in alzheimer's disease with pittsburgh compound-B,” Annals of Neurology, vol. 55, no. 3, pp. 306–319, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. A. M. Fagan, M. A. Mintun, R. H. Mach et al., “Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans,” Annals of Neurology, vol. 59, no. 3, pp. 512–519, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. A. M. Fagan, C. M. Roe, C. Xiong, M. A. Mintun, J. C. Morris, and D. M. Holtzman, “Cerebrospinal fluid tau/β-amyloid 42 ratio as a prediction of cognitive decline in nondemented older adults,” Archives of Neurology, vol. 64, no. 3, pp. 343–349, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Forsberg, H. Engler, O. Almkvist et al., “PET imaging of amyloid deposition in patients with mild cognitive impairment,” Neurobiology of Aging, vol. 29, no. 10, pp. 1456–1465, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Motter, C. Vigopelfrey, D. Kholodenko et al., “Reduction of beta-amyloid peptide(42), in the cerebrospinal fluid of patients with Alzheimers disease,” Annals of Neurology, vol. 38, no. 4, pp. 643–648, 1995. View at Google Scholar
  37. S. C. Samuels, J. M. Silverman, D. B. Marin et al., “CSF beta-amyloid, cognition, and APOE genotype in Alzheimer's disease,” Neurology, vol. 52, no. 3, pp. 547–551, 1999. View at Google Scholar · View at Scopus
  38. P. Edison, H. A. Archer, A. Gerhard et al., “Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195-PET and [11C]PIB-PET study,” Neurobiology of Disease, vol. 32, no. 3, pp. 412–419, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Nakamura, T. Kawamata, I. Akiguchi, M. Kameyama, N. Nakamura, and H. Kimura, “Expression of monoamine oxidase B activity in astrocytes of senile plaques,” Acta Neuropathologica, vol. 80, no. 4, pp. 419–425, 1990. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Hirvonen, M. Kailajärvi, T. Haltia et al., “Assessment of MAO-B occupancy in the brain with PET and 11 C-L-deprenyl-D 2: a dose-finding study with a novel MAO-B inhibitor, EVT 301,” Clinical Pharmacology and Therapeutics, vol. 85, no. 5, pp. 506–512, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. K. Blennow and H. Hampel, “CSF markers for incipient Alzheimer's disease,” Lancet Neurology, vol. 2, no. 10, pp. 605–613, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. J. Bauer, S. Strauss, U. Schreiter-Gasser et al., “Interleukin-6 and α-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices,” FEBS Letters, vol. 285, no. 1, pp. 111–114, 1991. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Strohmeyer, M. Ramirez, G. J. Cole, K. Mueller, and J. Rogers, “Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain,” Journal of Neuroimmunology, vol. 131, no. 1-2, pp. 135–146, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. O. C. Maes, S. Kravitz, Y. Mawal et al., “Characterization of α1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma,” Neurobiology of Disease, vol. 24, no. 1, pp. 89–100, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Matsubara, S. Hirai, M. Amari et al., “α1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia,” Annals of Neurology, vol. 28, no. 4, pp. 561–567, 1990. View at Google Scholar · View at Scopus
  46. J. Liebermann, L. Schleissner, K. H. Tachiki, and A. S. Kling, “Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia,” Neurobiology of Aging, vol. 16, no. 5, pp. 747–753, 1995. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Merched, Y. Xia, S. Visvikis, J. M. Serot, and G. Siest, “Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 1, pp. 27–30, 2000. View at Publisher · View at Google Scholar · View at Scopus
  48. M. C. Irizarry, “Biomarkers of Alzheimer Disease in Plasma,” NeuroRx, vol. 1, no. 2, pp. 226–234, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. N. R. Graff-Radford, J. E. Crook, J. Lucas et al., “Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease,” Archives of Neurology, vol. 64, no. 3, pp. 354–362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. S. Ray, M. Britschgi, C. Herbert et al., “Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins,” Nature Medicine, vol. 13, no. 11, pp. 1359–1362, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. H. Ghanbari, K. Ghanbari, I. Beheshti, M. Munzar, A. Vasauskas, and P. Averback, “Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker,” Journal of Clinical Laboratory Analysis, vol. 12, no. 5, pp. 285–288, 1998. View at Google Scholar · View at Scopus
  52. S. Levy, M. McConville, G. A. Lazaro, and P. Averback, “Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease,” Journal of Clinical Laboratory Analysis, vol. 21, no. 1, pp. 24–33, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. S. M. de la Monte and J. R. Wands, “The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease,” Frontiers in Bioscience, vol. 7, pp. d989–996, 2002. View at Google Scholar · View at Scopus
  54. D. Praticò, C. M. Clark, V. M.-Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald, “Increased 8,12-iso-iPF(2α)-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity,” Annals of Neurology, vol. 48, no. 5, pp. 809–812, 2000. View at Google Scholar · View at Scopus
  55. D. Praticò, C. M. Clark, F. Liun, V. Y.-M. Lee, and J. Q. Trojanowski, “Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease,” Archives of Neurology, vol. 59, no. 6, pp. 972–976, 2002. View at Google Scholar · View at Scopus
  56. E. E. Tuppo, L. J. Forman, B. W. Spur, R. E. Chan-Ting, A. Chopra, and T. A. Cavalieri, “Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease,” Brain Research Bulletin, vol. 54, no. 5, pp. 565–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. K. C. Bohnstedt, B. Karlberg, L.-O. Wahlund, M. E. Jönhagen, H. Basun, and S. Schmidt, “Determination of isoprostanes in urine samples from Alzheimer patients using porous graphitic carbon liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 796, no. 1, pp. 11–19, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. T. J. Montine, L. Shinobu, K. S. Montine et al., “No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls,” Annals of Neurology, vol. 48, no. 6, p. 950, 2000. View at Google Scholar · View at Scopus
  59. V. Thongboonkerd, “Practical points in urinary proteomics,” Journal of Proteome Research, vol. 6, no. 10, pp. 3881–3890, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. P. Formichi, C. Battisti, E. Radi, and A. Federico, “Cerebrospinal fluid tau, Aβ, and phosphorylated tau protein for the diagnosis of Alzheimer's disease,” Journal of Cellular Physiology, vol. 208, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. R. Craig-Schapiro, A. M. Fagan, and D. M. Holtzman, “Biomarkers of Alzheimer's disease,” Neurobiology of Disease, vol. 35, no. 2, pp. 128–140, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Citron, T. S. Diehl, G. Gordon, A. L. Biere, P. Seubert, and D. J. Selkoe, “Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 23, pp. 13170–13175, 1996. View at Publisher · View at Google Scholar · View at Scopus
  63. W. E. Van Nostrand, S. L. Wagner, W. R. Shankle et al., “Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 2551–2555, 1992. View at Google Scholar · View at Scopus
  64. A. E. Roher, J. D. Lowenson, S. Clarke et al., “β-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 22, pp. 10836–10840, 1993. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Lannfelt, H. Basun, C. Vigo-Pelfrey et al., “Amyloid β-peptide in cerebrospinal fluid in individuals with the Swedish Alzheimer amyloid precursor protein mutation,” Neuroscience Letters, vol. 199, no. 3, pp. 203–206, 1995. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Andreasen, C. Hesse, P. Davidsson et al., “Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease,” Archives of Neurology, vol. 56, no. 6, pp. 673–680, 1999. View at Publisher · View at Google Scholar · View at Scopus
  67. D. Galasko, L. Chang, R. Motter et al., “High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype,” Archives of Neurology, vol. 55, no. 7, pp. 937–945, 1998. View at Publisher · View at Google Scholar · View at Scopus
  68. H. Hampel, S. J. Teipel, T. Fuchsberger et al., “Value of CSF β-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment,” Molecular Psychiatry, vol. 9, no. 7, pp. 705–710, 2004. View at Google Scholar · View at Scopus
  69. P. Lewczuk, H. Esselmann, M. Otto et al., “Neurochemical diagnosis of Alzheimer's dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total tau,” Neurobiology of Aging, vol. 25, no. 3, pp. 273–281, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Mulder, S. N. M. Schoonenboom, L.-O. Wahlund et al., “CSF markers related to pathogenetic mechanisms in Alzheimer's disease,” Journal of Neural Transmission, vol. 109, no. 12, pp. 1491–1498, 2002. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Jensen, J. Schröder, M. Blomberg et al., “Cerebrospinal fluid Aβ42 is increased early in sporadic Alzheimer's disease and declines with disease progression,” Annals of Neurology, vol. 45, no. 4, pp. 504–511, 1999. View at Google Scholar · View at Scopus
  72. J. G. Csernansky, J. P. Miller, D. McKeel, and J. C. Morris, “Relationships among cerebrospinal fluid biomarkers in dementia of the Alzheimer type,” Alzheimer Disease and Associated Disorders, vol. 16, no. 3, pp. 144–149, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. R. B. DeMattos, K. R. Bales, M. Parsadanian et al., “Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease,” Journal of Neurochemistry, vol. 81, no. 2, pp. 229–236, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Hulstaert, K. Blennow, A. Ivanoiu et al., “Improved discrimination of AD patients using β-amyloid (1-42) and tau levels in CSF,” Neurology, vol. 52, no. 8, pp. 1555–1562, 1999. View at Google Scholar · View at Scopus
  75. M. Riemenschneider, S. Wagenpfeil, J. Diehl et al., “Tau and Aβ42 protein in CSF of patients with frontotemporal degeneration,” Neurology, vol. 58, no. 11, pp. 1622–1628, 2002. View at Google Scholar · View at Scopus
  76. M. Sjögren, L. Minthon, P. Davidsson et al., “CSF levels of tau, β-amyloid1-42 and GAP-43 in frontotemporal dementia, other types of dementia and normal aging,” Journal of Neural Transmission, vol. 107, no. 5, pp. 563–579, 2000. View at Google Scholar · View at Scopus
  77. N. J. Cairns, M. D. Ikonomovic, T. Benzinger et al., “Absence of Pittsburgh compound B detection of cerebral amyloid ß in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report,” Archives of Neurology, vol. 66, no. 12, pp. 1557–1562, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. O. Hansson, H. Zetterberg, P. Buchhave et al., “Prediction of Alzheimer's disease using the CSF Aβ42/Aβ40 ratio in patients with mild cognitive impairment,” Dementia and Geriatric Cognitive Disorders, vol. 23, no. 5, pp. 316–320, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. P. Lewczuk, H. Esselmann, M. Meyer et al., “The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide,” Rapid Communications in Mass Spectrometry, vol. 17, no. 12, pp. 1291–1296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. N. S. Schoonenboom, C. Mulder, G. J. Van Kamp et al., “Amyloid β 38, 40, and 42 species in cerebrospinal fluid: more of the same?” Annals of Neurology, vol. 58, no. 1, pp. 139–142, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. E. Portelius, E. Price, G. Brinkmalm et al., “A novel pathway for amyloid precursor protein processing,” Neurobiology of Aging. In press. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Portelius, H. Zetterberg, U. Andreasson et al., “An Alzheimer's disease-specific β-amyloid fragment signature in cerebrospinal fluid,” Neuroscience Letters, vol. 409, no. 3, pp. 215–219, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. J. Lewis, D. W. Dickson, W.-L. Lin et al., “Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP,” Science, vol. 293, no. 5534, pp. 1487–1491, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. E.-M. Mandelkow and E. Mandelkow, “Tau in Alzheimer's disease,” Trends in Cell Biology, vol. 8, no. 11, pp. 425–427, 1998. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Goedert, “Tau protein and the neurofibrillary pathology of Alzheimer's disease,” Trends in Neurosciences, vol. 16, no. 11, pp. 460–465, 1993. View at Google Scholar · View at Scopus
  86. K. Iqbal, A. D. C. Alonso, C.-X. Gong et al., “Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles,” Journal of Neural Transmission, Supplement, no. 53, pp. 169–180, 1998. View at Google Scholar · View at Scopus
  87. M. Vandermeeren, M. Mercken, E. Vanmechelen et al., “Detection of τ proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay,” Journal of Neurochemistry, vol. 61, no. 5, pp. 1828–1834, 1993. View at Publisher · View at Google Scholar · View at Scopus
  88. Y.-I. Morikawa, H. Arai, S. Matsushita et al., “Cerebrospinal fluid tau protein levels in demented and nondemented alcoholics,” Alcoholism: Clinical and Experimental Research, vol. 23, no. 4, pp. 575–577, 1999. View at Publisher · View at Google Scholar · View at Scopus
  89. Y. Y. Hu, S. S. He, X. Wang et al., “Levels of nonphosphorylated and phosphorylated tau in cerebrospinal fluid of Alzheimer's disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay,” American Journal of Pathology, vol. 160, no. 4, pp. 1269–1278, 2002. View at Google Scholar · View at Scopus
  90. H. Hampel, K. Buerger, R. Zinkowski et al., “Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study,” Archives of General Psychiatry, vol. 61, no. 1, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. K. Koopman, N. Le Bastard, J.-J. Martin, G. Nagels, P. P. De Deyn, and S. Engelborghs, “Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau181P,” Neurochemistry International, vol. 55, no. 4, pp. 214–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. G. Li, I. Sokal, J. F. Quinn et al., “CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: a follow-up study,” Neurology, vol. 69, no. 7, pp. 631–639, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. S. K. Maji, R. R. Ogorzalek Loo, M. Inayathullah et al., “Amino acid position-specific contributions to amyloid β-protein oligomerization,” The Journal of Biological Chemistry, vol. 284, no. 35, pp. 23580–23591, 2009. View at Publisher · View at Google Scholar · View at Scopus
  94. M. D. Kirkitadze, G. Bitan, and D. B. Teplow, “Paradigm shifts in Alzheimer's disease and other neurodegenerative disorders: the emerging role of oligomeric assemblies,” Journal of Neuroscience Research, vol. 69, no. 5, pp. 567–577, 2002. View at Publisher · View at Google Scholar · View at Scopus
  95. W. L. Klein, W. B. Stine Jr., and D. B. Teplow, “Small assemblies of unmodified amyloid β-protein are the proximate neurotoxin in Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 569–580, 2004. View at Publisher · View at Google Scholar · View at Scopus
  96. D. M. Walsh and D. J. Selkoe, “Aβ oligomers—a decade of discovery,” Journal of Neurochemistry, vol. 101, no. 5, pp. 1172–1184, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Hardy and D. J. Selkoe, “The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics,” Science, vol. 297, no. 5580, pp. 353–356, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. D. M. Walsh, I. Klyubin, J. V. Fadeeva et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo,” Nature, vol. 416, no. 6880, pp. 535–539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  99. T. Oda, P. Wals, H. H. Osterburg et al., “Clusterin (apoJ) alters the aggregation of amyloid β-peptide (Aβ1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress,” Experimental Neurology, vol. 136, no. 1, pp. 22–31, 1995. View at Publisher · View at Google Scholar · View at Scopus
  100. M. P. Lambert, A. K. Barlow, B. A. Chromy et al., “Diffusible, nonfibrillar ligands derived from Aβ1-42 are potent central nervous system neurotoxins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 11, pp. 6448–6453, 1998. View at Google Scholar · View at Scopus
  101. D. M. Walsh, D. M. Hartley, Y. Kusumoto et al., “Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates,” The Journal of Biological Chemistry, vol. 274, no. 36, pp. 25945–25952, 1999. View at Publisher · View at Google Scholar · View at Scopus
  102. D. M. Hartley, D. M. Walsh, C. P. Ye et al., “Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons,” Journal of Neuroscience, vol. 19, no. 20, pp. 8876–8884, 1999. View at Google Scholar · View at Scopus
  103. Q.-S. Chen, B. L. Kagan, Y. Hirakura, and C.-W. Xie, “Impairment of hippocampal long-term potentiation by Alzheimer amyloid β-peptides,” Journal of Neuroscience Research, vol. 60, no. 1, pp. 65–72, 2000. View at Google Scholar · View at Scopus
  104. J. Nalbantoglu, G. Tirado-Santiago, A. Lahsaïni et al., “Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein,” Nature, vol. 387, no. 6632, pp. 500–505, 1997. View at Publisher · View at Google Scholar · View at Scopus
  105. K. N. Dahlgren, A. M. Manelli, W. Blaine Stine Jr., L. K. Baker, G. A. Krafft, and M. J. Ladu, “Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability,” The Journal of Biological Chemistry, vol. 277, no. 35, pp. 32046–32053, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. I. Klyubin, D. M. Walsh, W. K. Cullen et al., “Soluble Arctic amyloid β protein inhibits hippocampal long-term potentiation in vivo,” European Journal of Neuroscience, vol. 19, no. 10, pp. 2839–2846, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. H.-W. Wang, J. F. Pasternak, H. Kuo et al., “Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus,” Brain Research, vol. 924, no. 2, pp. 133–140, 2002. View at Publisher · View at Google Scholar · View at Scopus
  108. J. P. Cleary, D. M. Walsh, J. J. Hofmeister et al., “Natural oligomers of the amyloid-β protein specifically disrupt cognitive function,” Nature Neuroscience, vol. 8, no. 1, pp. 79–84, 2005. View at Publisher · View at Google Scholar · View at Scopus
  109. F. G. De Felice, M. N. N. Vieira, M. N. L. Meirelles, L. A. Morozova-Roche, C. M. Dobson, and S. T. Ferreira, “Formation of amyloid aggregates from human lysozyme and its disease-associated variants using hydrostatic pressure,” FASEB Journal, vol. 18, no. 10, pp. 1099–1101, 2004. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Head, V. Pop, V. Vasilevko et al., “A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta,” The Journal of Neuroscience, vol. 28, no. 14, pp. 3555–3566, 2008. View at Google Scholar
  111. J. A. White, A. M. Manelli, K. H. Holmberg, L. J. Van Eldik, and M. J. LaDu, “Differential effects of oligomeric and fibrillar amyloid-β1-42 on astrocyte-mediated inflammation,” Neurobiology of Disease, vol. 18, no. 3, pp. 459–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Demuro, E. Mina, R. Kayed, S. C. Milton, I. Parker, and C. G. Glabe, “Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers,” The Journal of Biological Chemistry, vol. 280, no. 17, pp. 17294–17300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. Y.H. Chong, Y. J. Shin, E.O. Lee et al., “ERK1/2 activation mediates Aß oligomer-induced neurotoxicity via caspase-3 activation and Tau cleavage in rat organotypic hippocampal slice cultures,” The Journal of Biological Chemistry, vol. 281, no. 29, pp. 20315–20325, 2006. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Lesné, T. K. Ming, L. Kotilinek et al., “A specific amyloid-β protein assembly in the brain impairs memory,” Nature, vol. 440, no. 7082, pp. 352–357, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Townsend, G. M. Shankar, T. Mehta, D. M. Walsh, and D. J. Selkoe, “Effects of secreted oligomers of amyloid β-protein on hippocampal synaptic plasticity: a potent role for trimers,” Journal of Physiology, vol. 572, no. 2, pp. 477–492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  116. Y.-M. Kuo, M. R. Emmerling, C. Vigo-Pelfrey et al., “Water-soluble Aβ (N-40, N-42) oligomers in normal and Alzheimer disease brains,” The Journal of Biological Chemistry, vol. 271, no. 8, pp. 4077–4081, 1996. View at Publisher · View at Google Scholar · View at Scopus
  117. R. Kayed, E. Head, J. L. Thompson et al., “Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis,” Science, vol. 300, no. 5618, pp. 486–489, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. Y. Gong, L. Chang, K. L. Viola et al., “Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 18, pp. 10417–10422, 2003. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Pitschke, R. Prior, M. Haupt, and D. Riesner, “Detection of single amyloid β-protein aggregates in the cerebrospinal fluid of Alzheirner's patients by fluorescence correlation spectroscopy,” Nature Medicine, vol. 4, no. 7, pp. 832–834, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. D. G. Georganopoulou, L. Chang, J.-M. Nam et al., “Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 7, pp. 2273–2276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  121. J.-M. Lee, K. Blennow, N. Andreasen et al., “The brain injury biomarker VLP-1 is increased in the cerebrospinal fluid of Alzheimer disease patients,” Clinical Chemistry, vol. 54, no. 10, pp. 1617–1623, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. L. E. Rosengren, J.-E. Karlsson, M. Sjögren, K. Blennow, and A. Wallin, “Neurofilament protein levels in CSF are increased in dementia,” Neurology, vol. 52, no. 5, pp. 1090–1093, 1999. View at Google Scholar · View at Scopus
  123. M. Sjögren, P. Davidsson, J. Gottfries et al., “The cerebrospinal fluid levels of tau, growth-associated protein-43 and soluble amyloid precursor protein correlate in Alzheimer's disease, reflecting a common pathophysiological process,” Dementia and Geriatric Cognitive Disorders, vol. 12, no. 4, pp. 257–264, 2001. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Praticò, “Alzheimer's disease and oxygen radicals: new insights,” Biochemical Pharmacology, vol. 63, no. 4, pp. 563–567, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. T. J. Montine, M. F. Beal, M. E. Cudkowicz et al., “Increased CSF F2-isoprostane concentration in probable AD,” Neurology, vol. 52, no. 3, pp. 562–565, 1999. View at Google Scholar · View at Scopus
  126. D. Praticò, V. M.-Y. Lee, J. Q. Trojanowski, J. Rokach, and G. A. Fitzgerald, “Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo,” FASEB Journal, vol. 12, no. 15, pp. 1777–1783, 1998. View at Google Scholar · View at Scopus
  127. T. J. Montine, J. A. Kaye, K. S. Montine et al., “Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls,” Archives of Pathology & Laboratory Medicine, vol. 125, no. 4, pp. 510–512, 2001. View at Google Scholar
  128. Y. Harigaya, M. Shoji, T. Nakamura, E. Matsubara, K. Hosoda, and S. Hirai, “Alpha 1-antichymotrypsin level in cerebrospinal fluid is closely associated with late onset Alzheimer's disease,” Internal Medicine, vol. 34, no. 6, pp. 481–484, 1995. View at Google Scholar · View at Scopus
  129. T. Pirttila, P. D. Mehta, H. Frey, and H. M. Wisniewski, “α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease,” Neurobiology of Aging, vol. 15, no. 3, pp. 313–317, 1994. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Blum-Degena, T. Müller, W. Kuhn, M. Gerlach, H. Przuntek, and P. Riederer, “Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients,” Neuroscience Letters, vol. 202, no. 1-2, pp. 17–20, 1995. View at Publisher · View at Google Scholar · View at Scopus
  131. J. P. Jia, R. Meng, Y. X. Sun, W. J. Sun, X. M. Ji, and L. F. Jia, “Cerebrospinal fluid tau, Aβ1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia,” Neuroscience Letters, vol. 383, no. 1-2, pp. 12–16, 2005. View at Publisher · View at Google Scholar · View at Scopus
  132. M. Martínez, E. Fernández-Vivancos, A. Frank, M. De La Fuente, and A. Hernanz, “Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations,” Brain Research, vol. 869, no. 1-2, pp. 216–219, 2000. View at Publisher · View at Google Scholar · View at Scopus
  133. K. Yamada, K. Kono, H. Umegaki et al., “Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia,” Neuroscience Letters, vol. 186, no. 2-3, pp. 219–221, 1995. View at Publisher · View at Google Scholar · View at Scopus
  134. S. Engelborghs, M. De Brabander, J. De Crée et al., “Unchanged levels of interleukins, neopterin, interferon-γ and tumor necrosis factor-α in cerebrospinal fluid of patients with dementia of the Alzheimer type,” Neurochemistry International, vol. 34, no. 6, pp. 523–530, 1999. View at Publisher · View at Google Scholar · View at Scopus
  135. P. März, K. Heese, C. Hock et al., “Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients,” Neuroscience Letters, vol. 239, no. 1, pp. 29–32, 1997. View at Publisher · View at Google Scholar · View at Scopus
  136. E. Tarkowski, K. Blennow, A. Wallin, and A. Tarkowski, “Intracerebral production of tumor necrosis factor-α, a local neuroprotective agent, in Alzheimer disease and vascular dementia,” Journal of Clinical Immunology, vol. 19, no. 4, pp. 223–230, 1999. View at Publisher · View at Google Scholar · View at Scopus
  137. C. E. Teunissen, J. de Vente, H. W. M. Steinbusch, and C. De Bruijn, “Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid,” Neurobiology of Aging, vol. 23, no. 4, pp. 485–508, 2002. View at Publisher · View at Google Scholar · View at Scopus
  138. M. Flirski and T. Sobow, “Biochemical markers and risk factors of Alzheimer's disease,” Current Alzheimer Research, vol. 2, no. 1, pp. 47–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  139. B. Dubois, H. H. Feldman, C. Jacova et al., “Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria,” Lancet Neurology, vol. 6, no. 8, pp. 734–746, 2007. View at Publisher · View at Google Scholar · View at Scopus